Gallery
- PM Modi visit USAOnly the mirror in my washroom and phone gallery see the crazy me : Sara KhanKarnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
Hockey India on Monday announced the 20-member squad for the Men's Junior Asia Cup, a qual
- Harmanpreet Singh named FIH Player of the Year, PR Sreejesh gets best goalkeeper award
- World Boxing medallist Gaurav Bidhuri to flag off 'Delhi Against Drugs' movement on Nov 17
- U23 World Wrestling Championship: Chirag Chikkara wins gold as India end campaign with nine medals
- FIFA president Infantino confirms at least 9 African teams for the 2026 World Cup
- Hockey, cricket, wrestling, badminton, squash axed from 2026 CWG in Glasgow
Novavax's COVID-19 vaccine is 90% effective at preventing Covid infections Last Updated : 17 Dec 2021 05:07:30 PM IST Novavax's Covid-19 vaccine is 90 per cent effective at preventing Covid-19 illness, according to results from a Phase 3 clinical trial.
In addition to being highly effective in preventing Covid illness of any severity, the vaccine was 100 per cent effective in preventing moderate and severe disease that required hospitalisation, revealed the study published in the New England Journal of Medicine.For the trial, the team from University of Maryland included nearly 30,000 adult volunteers at 113 clinical sites in the US and six sites in Mexico.Approximately 20,000 participants received two doses of the vaccine spaced three weeks apart and 10,000 received placebos. The trial was conducted during the first few months of 2021, and tested only against Alpha variant, which was the predominant circulating strain.Most side effects were mild to moderate and transient. Fever was very rare. The most common side effects in the vaccine recipients included pain and tenderness at the injection site, headache, muscle aches and fatigue that lasted a day on average. None of the recipients developed serious reactions like heart inflammation (myocarditis) or blood clots."Our study results indicate that this vaccine is highly efficacious and very safe. In addition, this vaccine has many attractive features," said Karen Kotloff, Professor of Paediatrics at the varsity's School of Medicine."It is made from a small piece of protein, like many currently licensed vaccines in the US and has convenient refrigerator storage requirements, so it will be an important addition to the Covid-19 vaccine portfolio, in the US and in countries where supply is lacking," Kotloff added.Novavax is also a partner of Pune-based Serum Institute of India. The vaccine NVX-CoV2373 is already being locally manufactured by the company under the brand name Covovax - its vaccine for children aged above 3 years. It will be launched in the next six months, SII CEO Adar Poonawalla has said.Covavax is currently under trial and has shown excellent results down to the age of 3 years, Poonawalla said.IANS New York For Latest Updates Please-
Join us on
Follow us on
172.31.16.186